Prevalence, definition and clinical manifestations of polycystic ovary syndrome;Prevalencia, definición y manifestaciones clínicas del síndrome del ovario poliquístico

Endocrinologia y Nutricion

Volumn 53, Issue SUPPL. 1, 2006, Pages 15-33

  Diamanti Kandarakis, E ^a   Christakou, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinical approach; Definition; PCOS; Prevalence

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; GLUCOCORTICOID; MINOXIDIL; PHENYTOIN;

CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTRICHOSIS; INTERNATIONAL COOPERATION; MEDICAL LITERATURE; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; PREVALENCE; REVIEW;

EID: 34347272619     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(06)71166-4     Document Type: Article

References (90)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
2. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med. 2001;111:602-6.
3. Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.
4. Diamanti-Kandarakis E, Koulie CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: a hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006-11.
5. Asunción M, Calvo RM, San Millán JL, Sancho J, Ávila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
6. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 1999;51:779-86.
7. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ. 1986;293:355-9.
8. Azziz R, Woods K, Reyna R, Key T. The prevalence and features of the polycystic ovary syndrome in an unselected population. JCEM. 2004;89:2745-9.
9. Lo J, Feigenbaum S, Yang J, Pressman Al, Selby J, Go Al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1357-63.
10. Goodarzi M, Quiñones M, Azziz R, Rotter J, Hsueh W, Yang H. PCOS in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril. 2005;84:766-9.
11. Kauffman RP, Baker VM, Dimarino P, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol. 2002;187:1362-9.
12. King AC, Harris RB, Haskell WL. Effect of recruitment strategy on types of subjects entered into a primary prevention clinical trial. Ann Epidemiol. 1994;4:312-20.
13. Azziz R, Sánchez L, Knochenhauer E, Moran C, Lazenby J, Stephens K, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Met. 2004;89:453-62.
14. Carmina E, Rosato F, Jann A, Rizzo M, Longo R. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6.
15. Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in post-menopausal women - Marker of the metabolic syndrome. Maturitas. 2005;50:331-6.
16. Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metabol. 2006;91:781-5.
17. Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786-9.
18. Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95:14956-60.
19. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997;12:2641-8.
20. Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999;84:38-43.
21. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Gynecol. 2004;56:1-6.
22. Allemand MC, Tummon IS, Phy JL, Foong SC, Dumesic DA, Session DR. Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. Fertil Steril. 2006;85:214-9.
23. Legro R. PCOS: current and future treatment paradigms. Am J Obstet Gynecol. 1998;179:S101-8.
24. Lam PM, Ma RCW, Cheung LP, Chow CC, Chan JCN, Haines CJ. Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria. Hong Kong Med J. 2005;11:336-41.
25. Unluhizarci K, Gokce C, Atmaca H, Bayram F, Kelestimur F. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue. Exp Clin Endocrinol Diabetes. 2004;112:504-9.
26. Wijeyaratne C, Balen A, Barth J, Belchetz P. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol. 2002;57:343-50.
27. Kahsar-Miller MD, Nixon C, Boots L, Go R, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:53-8.
28. Atiomo W, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003;80:143-5.
29. Ehrmann DA, Kasza K, Azziz R, Legro R, Ghazzi M. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;90:66-71.
30. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002;16:263-72.
31. Ibáñez L, Valls C, Potau N, Marcos MV, De Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol. 2001;55:667-72.
32. Barker DJ, Clark PM. Fetal undernutrition and disease later in life. Ren Reprod. 1997;2:105-12.
33. Dimartino-Nardi J. Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl. 1999;88:67-72.
34. Rosenfield RL, Hirsutism. N Engl J Med. 2005;353:2578-88.
35. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol. 1987;123:209-12.
36. Deplewski D, Rosenfield R. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363-92.
37. Ehrmann DA. Medical progress: PCOS. N Engl J Med. 2005;352:1223-36.
38. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995-1007.
39. Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and acne. J Clin Endocrinol Metab. 1986;15:341-62.
40. Souter I, Sánchez LA, Pérez M, Bertolucci AA, Azziz R. The prevalence of androgen excess in women seeking treatment for minimal unwanted hair growth. Am J Obstet Gyn. 2004;191:1914-20.
41. Slayden C, Moran W, Sams L, Boots R, Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril. 2001;75:889-92.
42. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf). 1993;38:653-8.
43. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995;98:S95-8.
44. Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964-73.
45. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3:1873-6.
46. Cela E, Robertson C, Rush K, Kousta EI, White D, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocr. 2003;149:439-42.
47. Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenic alopecia in women. J Am Acad Dermatol. 1999;40:106-9.
48. Hunter M, Sterrett J. PCOS: it's not just infertility. Am Fam Phys. 2000;62:1079-88.
49. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16:1255-60.
50. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107-11.
51. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with PCOS. Arterioscler Thromb Vasc Biol. 1995;15:821-6.
52. Strowitzki T, Halser B, Demant T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with PCOS. Gynecol Endocrinol. 2002;16:45-51.
53. Kirchengast S, Gruber D, Sator M. The fat distribution index-a new possibility to quantify sex specific fat patterning in females. Homo. 1997;48:285-95.
54. Charnvises K, Weerakiet S, Tingthanatikul Y, Wansumrith S, Chanprasertyothin S, Rojanasakul A. Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:161-4.
55. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999;72:915-25.
56. Escobar-Morreale HF, San Millán JL, Smith RR, Sancho J, Witchel SF. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertil Steril. 1999;72:629-38.
57. Azziz R. The time has come to simplify the evaluation of the hirsute patient. Fertil Steril. 2000;74:870-2.
58. Bachega TA, Brenlha EM, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, et al. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations. J Clin Endocrinol Metab. 2002;87:786-90.
59. Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril. 1999;71:1075-8.
60. Erel CT, Senturk LM, Oral E, Colgar U, Ertungealp E. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. Gynecol Endocrinol. 1998;12:223.
61. Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17 hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab. 2006;90:1347-53.
62. Moran C, Azziz R. The role of the adrenal cortex in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001;28:63-75.
63. Glintborg D, Henriksen J, Andersen M, Hagen CI, Hangaard J, Rasmussen E, et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril. 2004;82:1570-9.
64. Rowe PJ, Comhaire FH, Hargreave TB. Female partner. En: World Health Organization manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press; 2000. p. 40-67.
65. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv. 2002;57:755-67.
66. Fauser BC, Pache TD, Lamberts SW, Hop WC, De Jong FH, Dahl KD. Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. J Clin Endocrinol Metab. 1991;73:811-7.
67. Taylor AE, McCourt B, Martin K, Anderson EJ, Adams J, Schoebfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab. 1997;82:2248-56.
68. Waldstreicher J, Santoro NF, Hall HJE, Filicori M, Crowley WF. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence of partial gonadotrophine desensitization. J Clin Endocrinol Metab. 1988;66:165-72.
69. Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14:2223-9.
70. Carmina E, Rosato F, Maggiore M, Gagliano AM. Prolactin secretion: correlation with the steroid pattern. Acta Endocrinol. 1984;105:99-104.
71. Zacur HA, Foster GV. Hyperprolactinemia and PCOS. Semin Reprod Endocrinol. 1992;10:236-45.
72. Kaltsas GA, Korbonits M, Isidori AM, Webb JA, Trainer PJ, Monson JP, et al. How common are polycystic ovaries and the PCOS in women with Cushing's syndrome. Clin Endocrinol (Oxf). 2000;53:493-500.
73. Kaltsas G, Isidori A, Kola B, Skelly R, Chew S, Jenkins P, et al. The value of the low dose dexamethasone test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003; 88:2634-43.
74. Matteoni CA, Younossi ZM, Gramlich T, Bopari N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
75. Setji T, Holland N, Sanders L, Pereira N, Diehl A, Brown A. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1741-7.
76. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-57.
77. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril. 2005;83:494.
78. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137-45.
79. Gaemers IC, Groen AK. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr Opin Lipidol. 2006;17:268-73.
80. Vgontzas AN, Legro R, Bixler E, Grayev A, Kales A, Chrousos G. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86:517-20.
81. Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1175-80.
82. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome. Sleep Med. 2002;3:401-4.
83. Hirschberg AL, Naessen S, Stridsberg M, Bystrom B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol. 2004;19:79-87.
84. García-Rudaz MC, Ropelato MG, Escobar ME, Veldhuis JD, Barontini M. Amplified and orderly growth hormone secretion in lean adolescence with PCOS. Eur J Endocrinol. 2002;147:207-16.
85. Comim FV, Spritzer PM. Increased growth hormone response to clonidine in nonobese normoinsulinemic patients with polycystic ovary syndrome. Fertil Steril. 2004;81:108-13.
86. Hara M, Ichikawa K, Minemura K, Kobayashi H, Suzuki N, Sakurai A, et al. Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report. Endocr J. 1993;40:207-11.
87. Fox R, Wardle PG, Clarke L, Hull MG. Acromegaloid bone changes in severe polycystic ovarian disease: an effect of hyperinsulinaemia? Case report. Br J Obstet Gynaecol. 1991;98:410-2.
88. Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Transplant. 2005;33:1073-7.
89. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:63-72.
90. Legro RS, Castracane VD, Kaufmann RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59:141-54.